Prosonix Ltd, which is developing inhaled respiratory products with ‘smart particle’ delivery, has appointed Ken Cunningham as a director and as chairman of its advisory board.
Dr Cunningham is executive chairman of PolyTherics Ltd and was the chief executive of Skyepharma Plc until August 2010.
Prosonix is a venture capital-financed company based in the Oxford Science Park in Britain.
Copyright 2011 Evernow Publishing Ltd